Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Alex P, Salam"'
Autor:
Josephine Bourner, Ravaka Randriamparany, Tsinjo Fehizoro Rasoanaivo, Emmanuelle Denis, Rindra Vatosoa Randremanana, Michel Vaillant, Alex Paddy Salam, Bronner P. Gonçalves, Piero Olliaro
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-11 (2023)
Abstract Introduction Conducting clinical research on treatments for emerging infectious diseases is often complicated by methodological challenges, such as the identification of appropriate outcome measures to assess treatment response and the lack
Externí odkaz:
https://doaj.org/article/ab69f31bbc584393ba2047022e34fe23
Autor:
Hung-Yuan Cheng, Clare E. French, Alex P. Salam, Sarah Dawson, Alexandra McAleenan, Luke A. McGuinness, Jelena Savović, Peter W. Horby, Jonathan A.C. Sterne
Publikováno v:
Emerging Infectious Diseases, Vol 28, Iss 8, Pp 1559-1568 (2022)
Ribavirin has been used widely to treat Lassa fever in West Africa since the 1980s. However, few studies have systematically appraised the evidence for its use. We conducted a systematic review of published and unpublished literature retrieved from e
Externí odkaz:
https://doaj.org/article/82bcbe709fa247f9b513e6c5dc7b253b
Autor:
Josephine Bourner, Marie Jaspard, Alex Paddy Salam, Camille Fritzell, Adebola Olayinka, Michel Vaillant, Bronner Goncalves, Cyril Erameh, Tansy Edwards, Michael Ramharter, Nnennaya Ajayi, Piero Olliaro
Publikováno v:
Wellcome Open Research, Vol 8 (2023)
Background: This is a standardized, pre-positioned protocol for the coordinated evaluation of Lassa fever therapeutics. The protocol is the product of discussions that took place in 2021 and 2022 among international investigators from a wide range of
Externí odkaz:
https://doaj.org/article/26970441ea50437db06a513186b46c97
Autor:
Alex P Salam, Alexandre Duvignaud, Marie Jaspard, Denis Malvy, Miles Carroll, Joel Tarning, Piero L Olliaro, Peter W Horby
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 16, Iss 3, p e0010289 (2022)
Ribavirin is currently the standard of care for treating Lassa fever. However, the human clinical trial data supporting its use suffer from several serious flaws that render the results and conclusions unreliable. We performed a systematic review of
Externí odkaz:
https://doaj.org/article/0035a81957e54460bac1f44288f08a61
Autor:
Adebola Tolulope Olayinka, Josephine Bourner, George O Akpede, Joseph Okoeguale, Chukwuyem Abejegah, Nnennaya A Ajayi, Christian Akude, Oluwafemi Ayodeji, Daniel G Bausch, Hilde de Clerck, Chioma Dan-Nwafor, Jake Dunning, Cyril Erameh, Justus Ndulue Eze, Pierre Formenty, Annelies Gillesen, Sulaiman Jalloh, Marie Jaspard, Tolulope Jegede, Jacob Maikere, Denis Malvy, Ephraim Ogbaini-Emovon, Olalekan Ezekial Ojo, Sylvanus Okogbenin, Kwame O'Neill, Maria-Lauretta Orji, Sampson Omagbemi Owhin, Michael Ramharter, Robert J Samuels, Nathan Shehu, Laura Merson, Alex Paddy Salam, Nzelle Delphine Kayem, Peter Horby, Chikwe Ihekweazu, Piero Olliaro
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 16, Iss 1, p e0010089 (2022)
BackgroundOnly one recommendation currently exists for the treatment of Lassa fever (LF), which is ribavirin administered in conjunction with supportive care. This recommendation is primarily based on evidence generated from a single clinical trial t
Externí odkaz:
https://doaj.org/article/b60018e400ac4403b5581934cbaa9fe3
Autor:
Tsinjo Fehizoro Rasoanaivo, Josephine Bourner, Ravaka Niaina Randriamparany, Théodora Mayouya Gamana, Voahangy Andrianaivoarimanana, Mily Harijaona Raherivelo, Harivelo Randriamampionona, Minoarisoa Rajerison, Mihaja Raberahona, Alex Paddy Salam, Tansy Edwards, Piero L Olliaro, Rindra Vatosoa Randremanana
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 15, Iss 12, p e0010064 (2021)
BackgroundAmong the many collaterals of the COVID-19 pandemic is the disruption of health services and vital clinical research. COVID-19 has magnified the challenges faced in research and threatens to slow research for urgently needed therapeutics fo
Externí odkaz:
https://doaj.org/article/40fa664e3e2f4b6bb66f96cdfbb5568f
Autor:
Laura Merson, Josephine Bourner, Sulaiman Jalloh, Astrid Erber, Alex Paddy Salam, Antoine Flahault, Piero L Olliaro
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 15, Iss 9, p e0009788 (2021)
BackgroundResearch is urgently needed to reduce the morbidity and mortality of Lassa fever (LF), including clinical trials to test new therapies and to verify the efficacy and safety of the only current treatment recommendation, ribavirin, which has
Externí odkaz:
https://doaj.org/article/a9d74b30ed184195b7b4f569fd7ece53
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 15, Iss 7, p e0009522 (2021)
Ribavirin is the only available Lassa fever treatment. The rationale for using ribavirin is based on one clinical study conducted in the early 1980s. However, reanalysis of previous unpublished data reveals that ribavirin may actually be harmful in s
Externí odkaz:
https://doaj.org/article/4763774884534bc790cd73d9a203fb9a
Publikováno v:
Emerging Infectious Diseases, Vol 26, Iss 10, Pp 2432-2434 (2020)
Externí odkaz:
https://doaj.org/article/c4614b93aff947cf9ff21cb3583b13bd
Autor:
Louise Sigfrid, Catrin Moore, Alex P. Salam, Nicola Maayan, Candyce Hamel, Chantelle Garritty, Vittoria Lutje, Brian Buckley, Karla Soares-Weiser, Rachel Marshall, Mike Clarke, Peter Horby
Publikováno v:
BMC Medicine, Vol 17, Iss 1, Pp 1-17 (2019)
Abstract Background Infectious disease epidemics are a constant threat, and while we can strengthen preparedness in advance, inevitably, we will sometimes be caught unaware by novel outbreaks. To address the challenge of rapidly identifying clinical
Externí odkaz:
https://doaj.org/article/487ce1622b6042f18be8c8536b5ed85d